Q-omics provides the consensus-scored STH profile across patient tissues and cancer cell-line models. STH expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STH is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, STH RNA expression shows 16,322 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where STH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STH survival associations across molecular data types. STH RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STH RNA expression–survival associations across cancer types. High STH expression shows unfavorable associations in ACC, COAD, CHOL and SARC, but favorable associations in BRCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STH RNA expression.
This table summarizes STH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for STH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STH shows higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher STH RNA expression in tumor versus normal tissue (log2 FC = +0.122, t-test p < 0.001).
This table shows molecular features associated with STH in patient tissues and cancer cell lines. In patient samples, STH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, STH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
